FDA WARNING_LETTER - Healthy Male - August 01, 2025

In September 2025, the U.S. Food and Drug Administration (FDA) issued a warning letter to Healthy Male, a company located in Tempe, Arizona, following a review of their website conducted in August 2025. The investigation revealed that the company is marketing compounded drug products, including tirzepatide, using claims that the FDA deems false or misleading. The FDA noted that Healthy Male promoted their compounded tirzepatide with statements claiming the products were "clinically proven" to deliver weight loss results. The agency clarified that compounded drugs are not FDA-approved, and such marketing falsely implies that these products have the same safety and efficacy standing as FDA-approved medications. Under the regulatory framework of the Federal Food, Drug, and Cosmetic Act (FDCA), specifically sections 502(a) and 502(bb), these medications are classified as misbranded. The distribution of these misbranded products into interstate commerce constitutes a violation of federal law. The FDA directed Healthy Male to take immediate corrective action, including ceasing the use of the misleading promotional language. The company is required to submit a written response within fifteen working days outlining the specific steps taken to address the violations and ensure future compliance. Failure to resolve these issues may lead to legal action, such as product seizures or permanent injunctions.